List of Sponsors
Contact: 60064 North Chicago, United States of America, Kristina Bokenewicz, email@example.com, www.abbvie.com
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Contact: MA 02210 Boston, USA,
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen), AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology. TEGSEDI is approved in the U.S., E.U. and Canada. WAYLIVRA is under regulatory review for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Boston, Massachusetts. Additional information about Akcea is available at www.akceatx.com.
Contact: 8045 Zurich, Switzerland
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), refractory generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). As the global leader in complement inhibition, Alexion is leveraging its experience in complement biology to pursue novel molecules and targets in the complement cascade. Alexion’s development efforts focus on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology.
Contact: 6300 Zug, Switzerland, firstname.lastname@example.org, www.alnylam.com
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases. Based on Nobel Prizewinning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of diseases with high unmet need. ONPATTRO® (patisiran) is the first-ever RNAi therapeutic approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults and by the EMA for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of investigational medicines, including six product candidates in Phase 3 studies. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Headquartered in Cambridge, MA, Alnylam employs over 1,100 people worldwide. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
Contact: 6300 Zug, Switzerland, Juan Vergez +41794671235, email@example.com, www.arvelletx.com
Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients with CNS disorders. Arvelle Therapeutics is responsible for the development and commercialization of cenobamate, an investigational anti-epileptic drug, in the European market. Arvelle Therapeutics is headquartered in Zug, Switzerland and is in the process of establishing a European footprint. For more details please visit: www.arvelletx.com
Contact: 600 California Street, 17th Floor, San Francisco, CA 94108, USA
Audentes Therapeutics, an Astellas company, is developing genetic medicines with the potential to deliver transformative value for patients. Based on our innovative scientific approach and industry-leading internal manufacturing capability and expertise, we have become the Astellas Center of Excellence for the newly created Genetic Regulation Focus Area. We are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown, with plans to expand our focus and geographic reach under Astellas. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
For more information regarding Audentes, please visit www.audentestx.com.
AveXis, a Novartis company, is the world’s leading gene therapy company, redefining the possibilities for patients and families affected by life-threatening genetic diseases through our innovative gene therapy platform.
Founded in 2013 and headquartered in Bannockburn, IL, USA, the goal of AveXis’ cutting-edge science is to address the underlying, genetic root cause of diseases. AveXis pioneered foundational research, establishing AAV9 as an ideal vector for gene transfer in diseases affecting the central nervous system, laying the groundwork to build a best-in-class, transformational gene therapy pipeline. AveXis received its first U.S. Food and Drug Administration approval in May 2019 for the treatment of spinal muscular atrophy (SMA). AveXis is also developing therapies for other genetic diseases, including Rett syndrome, a genetic form of amyotrophic lateral sclerosis (ALS) SOD1 and Friedreich’s ataxia. For additional information, please visit www.avexis.com.
Contact : 13353 Berlin, Germany, Yildiz Caska, +49 304 681 64 71, firstname.lastname@example.org, www.bayer.com
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. For more information, go to www.bayer.com
Contact: À Av. Siderurgia Nacional, 4745-457 Coronado, Portugal, www.bial.com
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com
Contact: 94257 Paris, France, Mehdi Metheni, +33770124096, email@example.com, www.dravet-syndrome.com
BIOCODEX is a French independent pharmaceutical company relying on a global network of scientists and partners. This allowing to acquire, over the years, expertise in specific therapeutic areas, such as in orphan disease in children epilepsy, and now enables patients in over 100 countries to have access to its innovative medication. Powered by an industrial vision and innovation, BIOCODEX is committed to provide the best care to patients, emphasizing work on the long term in a constant dialogue with healthcare professionals.
Contact: 6340 Baar, Switzerland, Eva Hoff, firstname.lastname@example.org, www.biogen.com
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, acute neurology, Alzheimer’s disease and dementia. Biogen also manufactures and commercializes biosimilars of advanced biologics.
To learn more, please visit www.biogen.com.
Contact: 82152 Planegg, Germany, Benedikt Weiss, +49 89 895574-910, www.biomax.com
Biomax Informatics provides software solutions for efficient decision making and knowledge management in the life science market.
All standard products are based on the BioXM™ technology platform:
• NeuroXM™ is the one-stop-shop to decipher brain physiology performing automated analyses of brain connectomics.
• AILANI™, the Artificial Intelligence LANguage Interface, provides unique semantic search capabilities that catalyze digital change and accelerate the innovation cycle.
• The Clinical Integration System ensures access to real world evidence data, which is critical to train Artificial Intelligence to support clinical decisions at the point of care.
Founded in 1997 and headquartered in Planegg, Germany, Biomax is ISO 9001 and ISO 27001 certified.
Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company. We specialise in innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson's disease. We are highly committed to improving the quality of life for People with Parkinson's disease.
Contact: 72076 Tuebingen, Germany, email@example.com www.cegat.de
CeGaT GmbH, founded in Tübingen, Germany, is a world leader in gene analyses for a wide range of medical, research, and pharmaceutical applications.
The company combines the latest sequencing technology with its many years of medical expertise – dedicated to identifying the genetic cause of disease and supporting patient care. For research and the pharmaceutical industry, CeGaT offers a broad portfolio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with own findings.
The owner-managed company stands for independence, an extensive personal customer service, and the highest quality. To maintain the best results, all project steps are carried out in-house and under scientific supervision. CeGaT's laboratory is accredited according to CAP/CLIA and DIN EN ISO 15189, hence meeting high international standards.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb company and Juno Therapeutics, a Bristol-Myers Squibb company. '
Contact: 8020 Graz, Austria, Alice Wellisch, +43 316 7234560, firstname.lastname@example.org, www.cnsystems.com
CNSystems is world market leader for non-invasive hemodynamic monitoring and diagnosis solutions with over 20 years of experience.
Our Task Force TOUCH platform is the state-of-the-art tool for an easy and efficient diagnostic assessment of syncope as well as autonomic function or any application where a comprehensive analysis of the cardiovascular system is required.
The focus lies in providing enhanced hemodynamic information and first class medical treatment in an easy and cost-efficient way closing the cycle of prevention, (early) diagnosis and monitoring.
Contact: 92121 San Diego, USA , www.cortechslabs.com
CorTechs Labs offers the most advanced artificial-intelligence-based methods for MR imaging, delivering accurate and clinically relevant quantitative data used in the diagnosis of brain diseases. NeuroQuant is the first and most widely used clinical solution for brain MRI quantification in the world, analyzing over 8,000 scans per month. NeuroQuant measures more brain structures, supports a wider age range, and compares volumetric data to a dynamic normative database more extensive than any other FDA-approved solution.
Contact: 1000 Brussels, Belgium, Donna Walsh, email@example.com, www.efna.net,
The European Federation of Neurological Associations [EFNA] is an umbrella group representing pan-European neurology patient groups.Our slogan ‘Empowering Patient Neurology Groups’ encapsulates our goals as an Association. We strive to add capacity to our members – allowing them to be the most effective advocates possible in their own disease specific areas.EFNA embraces the concept of Partnership for Progress – working at a high level with relevant stakeholders from the fields of policy, medical, scientific/research, industry, patient partners and other key opinion leaders.
Contact: 1214 Vernier-Geneve, Switzerland, www.lilly.com
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
Contact: 72076 Tübingen, Germany, Holm Graessner, info(at)ern-rnd.eu, www.ern-rnd.eu
The European Reference Network for Rare Neurological Diseases (ERN-RND) is a virtual network of European hospitals with specific and well-known expertise in rare neurological diseases (RNDs). The main objective of the network is to support around 500,000 people in Europe affected by an RND in getting a timely and accurate diagnosis as well as receiving the best treatment and care.
Follow us on Twitter and Facebook, subscribe to our YouTube channel.
Contact: 4866 Unterach, Austria, Nadja Graf, +43766520555606, firstname.lastname@example.org, www.everpharma.com
We are a globally successful pharmaceutical specialist. At our headquarters in Unterach, Austria, we are always on the search for new therapeutic solutions aimed at improving both the patients’ well-being and quality of life.
Cerebrolysin® is a biotechnologically manufactured original neuropeptide solution that stimulates neurotrophic regulation in the central nervous system. It is indicated for the treatment of stroke, traumatic brain injuries and cognitive impairment/dementia.
Tachyben is used for intravenous treatment of hypertensive emergencies. It is used to control lowering of blood pressure in hypertensive patients during and/or after surgery in cases of severe forms of hypertensive disease.
Among other agents, our product portfolio is strengthened with Dacepton®/Dopaceptin® (apomorphine hydrochloride) for the treatment of disabling motor symptoms in the advanced stage of Parkinson´s disease. We focus on the complete Package of Care including D-mine® Medical Devices for the intermittent and continuous drug delivery.
Recognizing current trends, we keep to our endeavor for further and constant improvement of our patient-oriented services.
Contact: 08174 Barcelona, Spain
Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. We produce essential plasma-derived medicines and a comprehensive portfolio of solutions for hospitals, pharmacies and healthcare professionals to deliver efficient, expert medical care. With more than 15 years of rigorous scientific research in Alzheimer’s, Grifols is committed to continue investigating this disorder and advancing treatment of neurological conditions.
For more information please visit: https://www.grifols.com/
Contact: Cambridge, United Kingdom
GW Pharmaceuticals (GW) is a pioneering, global biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and medicines. GW’s mission is to transform the lives of patients with rare and severe illnesses through developing and delivering rigorously tested cannabinoid-based pharmaceutical medicines with well documented safety and efficacy profiles, manufactured to the highest pharmaceutical standards and approved by medicines regulators. The Company’s extended pipeline covers a range of therapeutic areas including neurology, oncology and psychiatry. GW is listed on the NASDAQ Global Market (GWPH).
Contact: 4521 Schiedberg, Austria, Alexander Lechner, 7251-222-40, email@example.com
g.tec medical engineering GmbH developed the first commercially available Brain-Computer Interface (BCI) system in 1999 and now sells this kind of technology worldwide. BCI systems are mainly used in the research sector, but g.tec develops also applications for the clinical market. One system, called recoveriX, is the first rehabilitation system for stroke patients that pairs mental activities with motor functions. The other system is called mindBEAGLE, which uses BCI technology for quick and easy assessment of Disorder of Consciousness (DOC) patients and even provides basic communication with some of them.
Contact: 4070 Basel, Switzerland, +41616881111, firstname.lastname@example.org, www.roche.com ,
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Contact: 3012 Leuven, Belgium, Wim Van Hecke, 0032 16 369 000, email@example.com, www.icometrix.com
Icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MR and CT scans for patients with multiple sclerosis, brain trauma, epilepsy, Alzheimer’s disease, dementia, etc. The fully automated icobrain software is FDA cleared and has market clearance in the USA, Europe, Japan, Canada, Brazil, and Australia. Today, icometrix is internationally active, and the icobrain software is used in 100+ hospitals and icometrix works with some of the largest healthcare providers and pharmaceutical companies on the evaluation of trials of novel drugs for neurological diseases.
Contact: 75015 Paris, France, Jean-Louis Benezeth, +33 1 43 20 16 40 , firstname.lastname@example.org
Impeto Medical is an innovative French company created in 2005, which develops and markets in more than 35 countries SUDOSCAN, a novel medical device allowing the detection and follow-up of autonomic peripheral neuropathy (small fiber neuropathy). SUDOSCAN is a quick diagnostic test (three minutes only), non-invasive, quantitative and objective. This patented technology assesses the sweat glands function by applying a low voltage on feet and hands, reflecting thereby the autonomic small fibers state that innervate sweat glands. More than 100 scientific publications in peer reviewed journals have demonstrated the reliability and benefits of SUDOSCAN in neurology, diabetology, chemo-induced neuropathies and other serious pathologies like hereditary amyloidosis. SUDOSCAN is also included in several international therapeutic guidelines. For more information, visit our website : https://www.impeto-medical.com/
Contact: 3011 Bern, Switzerland, Irina Anich, info(at)neuro-uro.org, www.neuro-uro.org
The International Neuro-Urology Society (INUS) is a medical and scientific non-profit organization. It is the only society which deals exclusively with neuro-urology. Its aim is to improve neuro-urological knowledge worldwide by education, research and providing networking opportunities.
Contact: 4123, Allschwill, Switzerland, Ewelina Swierad, eswierad(at)its.jnj.com; www.janssen.com
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.
Contact: 2500 Valby, Denmark
Lundbeck is a global pharmaceutical company specialized in discovering and developing innovative treatments for brain diseases. At Lundbeck, we are tirelessly dedicated to restoring brain health, so every person can be their best. www.lundbeck.com #brainhealth #progressinmind
Contact: 1311 Tolochenaz, Switzerland
Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together.
Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value — for healthcare systems, providers, and the people they serve.
Learn more at Medtronic.com.
At the biopharma business of Merck, we have a long history of focusing on the needs of our customers and patients and we are constantly seeking innovative solutions to advance the state of care in the area of multiple sclerosis (MS). We are committed to developing new treatment options and devices, as well as enhanced patient support services for people living with a neurological disease. Our MS product portfolio includes two complementary products, Rebif® (interferon beta-1a) for relapsing forms of multiple sclerosis (MS), and MAVENCLAD® (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis (RMS). For further details please visit: www.merckneurology.com
Contact: 53562 WI, United States of America, Filomena Goncalves, +1 608-829-8500, email@example.com, www.natus.com
Natus Medical Incorporated
Solutions that span the spectrum of neuro care. Natus is global market leader that provides diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care and neurosurgery.
Natus delivers clinician-led solutions that improve outcomes and enhance care for neuro patients through leading-edge equipment, service, education and supplies. Healthcare solutions with one thing in mind. You.
Contact: 92130 San Diego, United States of America
Neurocrine Biosciences, Inc. discovers and develops innovative and life‐changing pharmaceuticals utilizing our novel R&D platform. Neurocrine's efforts are focused on conditions with high unmet medical needs, specifically in neurologic, psychiatric, and endocrine based diseases and disorders.
Novartis is a leading global medicines company that is reimagining medicine to improve and extend people’s lives, using innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. Find out more at www.novartis.com.
Contact: 90230 Oulu, Finland, Anne Lämsä, +358 20 741 3380, firstname.lastname@example.org,
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. Optomed’s customers consist of international health care organisations, hospitals and leading global medical technology companies and distributors. Our camera products have medical approvals in all key markets, including CE (Europe) and FDA (USA), and CFDA (China) for Smartscope PRO.
Contact: EC4N 6EU London, United Kingdom, medinfo(at)orchard-tx.com
Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.
Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Contact: NY 10017 New York, USA, +1 212-733-2323, info@Pfizer.com, www.pfizer.com
Pfizer Inc.: Breakthroughs that change patients’ lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Contact: Dublin, Ireland, Sarah Bourgeois, +41 41 743 47 75, sbourgeois(at)ptcbio.com
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
Contact: 3012 KM Rotterdam, The Netherlands, Jolanta Leonaite, (+31) 108411749, email@example.com, www.quantib.com
Quantib, market leader in artificial intelligence tools for radiology, strives for faster and more accurate diagnoses, supporting adequate and timely patient care. Using advanced machine learning techniques, Quantib’s products can detect changes in tissue sooner than would be possible with the naked eye. Quantib has multiple machine-learning products cleared by FDA and/or CE marked. These products are focused detection of changes in the brain related to diseases such as dementia and MS. Simultaneously, the company is collaborating with, amongst others, Erasmus MC Rotterdam and UMC Utrecht, for the development of other AI applications.
Contact: 01821 Billerica, United States of America, Marisa Kradjian, firstname.lastname@example.org, www.quanterix.com Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Simoa is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Contact: 02140 Cambridge, USA, Ahmad Alrawi, 203-895-8355, Aalrawi@rapharma.com, www.rapharma.com
Ra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade.
Ra Pharma’s lead clinical candidate is zilucoplan, an investigational, synthetic, macrocyclic peptide discovered using the Company’s proprietary drug discovery technology. The peptide is designed to bind complement component 5 (C5) with sub-nanomolar affinity and allosterically inhibit its cleavage into C5a and C5b upon activation of the classical, alternative, or lectin pathways. Zilucoplan is being developed for generalized myasthenia gravis (gMG), immune-mediated necrotizing myopathy (IMNM), amyotrophic lateral sclerosis (ALS), and other tissue-based complement-mediated disorders with high unmet medical need.
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Contact: 1019GM Amsterdam, Netherlands, Job den Hollander, Job.Den.Hollander@Tevaeu.com, www.tevapharm.com
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 43,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
Contact: 1070 Brussels, Belgium, Laurent Schots, Tel: +32 2 559 99 99, Fax: +32 2 559 99 00, email@example.com, https://www.ucb.com
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, UCB generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Contact: SW192RL London, United Kingdom, Olivia Thomas, +442087151812, firstname.lastname@example.org, www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.hop online with great offers.
Contact: 19103 Philadelphia, United States of America, Joey-Rose Jester, email@example.com, firstname.lastname@example.org, https://shop.lww.com
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers, students, and the next generation of healthcare providers. With a focus on clinical effectiveness, research and learning, safety and surveillance, and interoperability and data intelligence, our proven solutions drive effect decision-making and consistent outcomes across the continuum of care.
Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. Based on a valuable heritage and strongly focused on the future, its goal is to improve people’s health through the development of innovative and quality healthcare solutions.
Zambon products are commercialized in 87 countries. The company has 20 subsidiaries in three different continents – Europe, America and Asia – and owns manufacturing units in Italy, Switzerland, China and Brazil.
The company today has a strong focus on the treatment of rare diseases and specialties, on top of respiratory, pain management and women’s care. Zambon was established in 1906 in Italy and today counts 2,500 employees all over the world. For further information, please visit www.zambon.com